hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06321523, orgStudyIdInfo id: B3461122, briefTitle: A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM).This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective., conditionsModule conditions: Transthyretin Amyloid Cardiomyopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: Tafamidis 61 milligrams, outcomesModule primaryOutcomes measure: Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification, primaryOutcomes measure: Change from baseline in six-minute walk test, primaryOutcomes measure: Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS), primaryOutcomes measure: Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration, primaryOutcomes measure: Change From Baseline in Troponin I and Troponin T, primaryOutcomes measure: number of participants with Any Heart Block, primaryOutcomes measure: number of participants with Atrioventricular (AV) block, primaryOutcomes measure: Change From Baseline in Left Ventricular Ejection Fraction, primaryOutcomes measure: Change From a Baseline in Diastolic function grades, primaryOutcomes measure: Change from Baseline in Left Ventricular Wall Thickness, primaryOutcomes measure: Change From Baseline in Global Longitudinal Strain scores, secondaryOutcomes measure: Frequency of cardiovascular hospitalizations, secondaryOutcomes measure: Frequency of death due to any cause, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pfizer, city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06321510, orgStudyIdInfo id: A7471070, briefTitle: A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer.This study is seeking participants who:* have lung cancer that could not be controlled.* have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work.* have received dacomitinib for their lung cancer.All participants in this study had received dacomitinib. Dacomitinib is a tablet that is taken by mouth at home. They continued to take dacomitnib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective., conditionsModule conditions: Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Percentage of patients with dacomitinib dosage change and reasons, primaryOutcomes measure: Percentage of patients with dacomitinib treatment discontinuation, secondaryOutcomes measure: Real-world overall survival (rwOS), secondaryOutcomes measure: Real-world progression-free survival, secondaryOutcomes measure: Real-world best objective response rate (rwORR), secondaryOutcomes measure: real-world intracranial response rate (rwIC-ORR), secondaryOutcomes measure: real-world extracranial response rate (rwEC-ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06321497, orgStudyIdInfo id: 85711, briefTitle: Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-05, primaryCompletionDateStruct date: 2027-02-28, completionDateStruct date: 2028-02-28, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Peninsula Health, class: OTHER_GOV, collaborators name: Monash University, collaborators name: Baxter Healthcare Corporation, descriptionModule briefSummary: Lung protective ventilation with low tidal volumes and low driving pressure are known to reduce mortality in mechanically ventilated patients with acute respiratory failure. This reduction in mortality is known be due to reduction of ventilator induced lung injury that occurs due to high tidal volumes and high driving pressure. When receiving such mechanical ventilation, some patients develop hypercapnia and associated hypercapnic acidosis. Such patients have an increased risk of mortality. While the exact reasons for such increase in mortality is not known, it is recommended to minimise hypercapnia and hypercapnic acidosis during lung protective ventilation. Minimally invasive extracorporeal carbon dioxide removal (ECCO2R) devices are shown to reduce hypercapnia and hypercapnic acidosis. There are several devices that are currently available in the current clinical practice. However, the effect of these devices on reduction in ventilator induced lung injury is not clearly demonstrated. This study aims to assess the use of an ECCO2R device called Prismalung in reducing ventilator induced lung injury. PrismaLung is currently used in our intensive care unit. This assessment is done by measuring interleukins in bronchoalveolar lavage fluid and blood interleukin levels as well as clinical assessment including the reduction of driving pressure., conditionsModule conditions: ARDS, Human, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Extracorporeal carbon dioxide removal, outcomesModule primaryOutcomes measure: Reduction in driving airway pressures, secondaryOutcomes measure: Reduction in pulmonary inflammation assessed by interleukins in lung, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Frankston Hospital, status: RECRUITING, city: Frankston, state: Victoria, zip: 3199, country: Australia, contacts name: Ravindranath Tiruvoipati, PhD, role: CONTACT, phone: 0431279347, email: rtiruvoipati@phcn.vic.gov.au, contacts name: Sachin Gupta, FCICM, role: CONTACT, email: sachingupta@phcn.vic.gov.au, geoPoint lat: -38.14458, lon: 145.12291, hasResults: False
protocolSection identificationModule nctId: NCT06321484, orgStudyIdInfo id: 23-493, briefTitle: Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-11-30, completionDateStruct date: 2031-10-31, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Dana-Farber Cancer Institute, class: OTHER, collaborators name: ImmunityBio, Inc., descriptionModule briefSummary: The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy combined with IL-15 superagonist (N-803) in recurrent, high grade ovarian cancer (HGOC).Names of the study therapies involved in this study are:* CIML NK (cellular therapy)* N-803 (a novel immune-cell stimulator), conditionsModule conditions: Platinum-resistant Ovarian Cancer, conditions: Recurrent Ovary Cancer, conditions: Ovarian Cancer, conditions: Ovarian Carcinoma, conditions: Ovarian Carcinoma, Recurrent, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Cytokine-Induced Memory-like Natural Killer Cells, interventions name: IL-15 Superagonist, outcomesModule primaryOutcomes measure: Maximum Tolerated Dose (MTD) (Cohort 1), primaryOutcomes measure: Dose Limiting Toxicity (DLT) (Cohort 1), secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: Median Progression Free Survival (PFS), secondaryOutcomes measure: Clinical Benefit Rate (CBR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: 6 months Progression Free Survival (PFS6), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Rebecca Porter, MD, PhD, role: CONTACT, phone: 617-632-2334, email: rebecca_porter@dfci.harvard.edu, contacts name: Rebecca Porter, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, locations facility: Dana-Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Rebecca Porter, MD, PhD, role: CONTACT, phone: 617-632-2334, email: Rebecca_Porter@dfci.harvard.edu, contacts name: Rebecca Porter, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06321471, orgStudyIdInfo id: STUDY00002858, briefTitle: AeviceMD for Pediatric Asthma Management, acronym: APAM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Irina Dralyuk, class: OTHER, collaborators name: AEvice Health Pte Ltd, descriptionModule briefSummary: A wearable remote patient monitor (AeviceMD) is to be used to monitor the respiratory health of pediatric asthma patients in this pilot study. Patients prescribed with AeviceMD should be able to gain better control over their disease during home management. Physicians should be able to optimize treatment for these patients using objective data collected from and of these patients outside of the clinic. The AeviceMD should also be used as a remote auscultation device for teleconsultations., conditionsModule conditions: Asthma, conditions: Asthma in Children, conditions: Pediatric Asthma, conditions: Chronic Respiratory Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: AeviceMD, outcomesModule primaryOutcomes measure: To evaluate the effectiveness of implementing home monitoring technology for asthma patients in delivering care to patients and in extension determine, if Aevice Medical Device can improve home management of Asthma for pediatrics patients., secondaryOutcomes measure: To determine if the AeviceMD is effective as a remote auscultation tool for the facilitation of teleconsultations., eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Cedars-Sinai Medical Center, city: Los Angeles, state: California, zip: 90048, country: United States, contacts name: Bobby Marker, role: CONTACT, phone: 310-423-0901, email: Robert.Marker@cshs.org, contacts name: Irina Dralyuk, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06321445, orgStudyIdInfo id: ChatGptASAscore, briefTitle: The Success of ChatGPT in Providing American Society of Anesthesiologist (ASA) Scores, acronym: ASA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Kanuni Sultan Suleyman Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Patients applied to the anesthesia clinics of Health Science University Istanbul Kanuni Sultan Suleyman Training and Research Hospital and Basaksehir Cam and Sakura City Hospital were included in the study. Evaluation forms which will be filled in every preoperative examinations will be saved in the hospitals systems. Patients datas without indentification informations will be asked to ChatGpt to give anesthesiological risc scores. This scores will be compared with the scores already given by anesthesiologists., conditionsModule conditions: Artificial Intelligence, conditions: Preoperative Evaluation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule interventions name: providing ASA score, outcomesModule primaryOutcomes measure: The Success of ChatGPT in Providing American Society of Anesthesiologist (ASA) Scores, secondaryOutcomes measure: The Success of ChatGPT in clinical decisions, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Health Science University İstanbul Kanuni Sultan Süleyman Education and Training Hospital, status: RECRUITING, city: Istanbul, zip: 34303, country: Turkey, contacts name: Engin ihsan Turan, role: CONTACT, phone: 05382431114, email: enginihsan@hotmail.com, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06321406, orgStudyIdInfo id: KayseriCHdysphagia, briefTitle: Effect of Superficial Neuromuscular Stimulation in Post-stroke Dysphagic Patients., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-06-15, completionDateStruct date: 2024-07-15, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: Kayseri City Hospital, class: OTHER_GOV, descriptionModule briefSummary: Swallowing disorder in stroke patients is a significant cause of morbidity and mortality as it can cause aspiration pneumonia. Electrical stimulation has proven to be effective in post-stroke dysphagic patients.10 patients who have symptoms of post-stroke dysphagia, meet the inclusion criteria and volunteer to participate will be included in the study. Included patients will be randomized into 2 groups. The exercise program will be applied to both groups as a home program for 4 weeks., conditionsModule conditions: Dysphagia, conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: NMES (neuromuscular electrical stimulation), interventions name: Exercise, outcomesModule primaryOutcomes measure: Ultrasonographic measurements, secondaryOutcomes measure: Functional Oral Intake Scale (FOIS), secondaryOutcomes measure: Swallowing Function Screening Test (EAT-10), secondaryOutcomes measure: GUSS (Gagging Swallowing Screening Test), secondaryOutcomes measure: Modified Mann Swallowing Ability Assessment Test (MMASA), secondaryOutcomes measure: SWAL-QOL (The impact of swallowing disorders on quality of life questionnaire), eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: health sciences university Kayseri medicine faculty, city: Kayseri, zip: 38080, country: Turkey, geoPoint lat: 38.73222, lon: 35.48528, hasResults: False
protocolSection identificationModule nctId: NCT06321367, orgStudyIdInfo id: 202401002, secondaryIdInfos id: 82070613, type: OTHER_GRANT, domain: the National Natural Sciences Foundation of China, secondaryIdInfos id: 82370638, type: OTHER_GRANT, domain: the National Natural Sciences Foundation of China, secondaryIdInfos id: 2022RC1212, type: OTHER_GRANT, domain: the Science and Technology Innovation Program of Hunan Province, secondaryIdInfos id: 2023JJ10095, type: OTHER_GRANT, domain: he Natural Science Foundation of Hunan Province China, briefTitle: Model to Predict Coinfection in Elderly Patients With COVID-19, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-20, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2023-06-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Xiangya Hospital of Central South University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about the clinical characteristics and construction of a predictive model in elderly COVID-19 patients. The main question it aims to answer is the main clinical characteristics and risk factors of elderly COVID-19 patients. Participants will not be asked to do any other intervening measure., conditionsModule conditions: Covid19, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Coinfection, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xiangya Hospital of Central South University, city: Changsha, state: Hunan, zip: 410000, country: China, geoPoint lat: 28.19874, lon: 112.97087, hasResults: False
protocolSection identificationModule nctId: NCT06321328, orgStudyIdInfo id: ChatGpt postoperative ICU, briefTitle: Success of ChatGPT in Determining the Need for Postoperative Intensive Care, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-16, primaryCompletionDateStruct date: 2024-04-16, completionDateStruct date: 2024-05-01, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Kanuni Sultan Suleyman Training and Research Hospital, class: OTHER, descriptionModule briefSummary: This is a prospective, observational study to be conducted at Sağlık Bilimleri University Istanbul Kanuni Sultan Süleyman Training and Research Hospital and Başakşehir Çam and Sakura City Hospital. The study aims to record various preoperative and postoperative data of patients who have undergone surgeries, specifically those with ASA scores of III and IV or those indicated to potentially need postoperative intensive care. Data points include patient demographics, type of surgery, ASA score, comorbidities, lab and imaging findings, and both actual and ChatGPT version 4 predicted outcomes regarding postoperative intensive care needs, anesthesia methods, duration of stay in intensive care and the hospital, and 30-day mortality rates. ChatGPT version 4's predictions will be compared with actual outcomes and anesthesiologist decisions., conditionsModule conditions: Artificial Intelligence, conditions: Intensive Care Unit, conditions: PACU Length of Stay, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 398, type: ESTIMATED, outcomesModule primaryOutcomes measure: Intensive care predictions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: istanbul Kanuni Sultan Süleyman Education and Training Hospital, city: Istanbul, zip: 34303, country: Turkey, contacts name: Yeşim Özay, role: CONTACT, phone: 0090212 404 15 00, phoneExt: 2144, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06321315, orgStudyIdInfo id: KSUESRAKARATASOKYAY006, briefTitle: The Effect of Case-based Teaching on Midwifery Undergraduate Students, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-19, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Kahramanmaras Sutcu Imam University, class: OTHER, descriptionModule briefSummary: Case-based teaching will be applied to second year midwifery undergraduate students. The intervention group (case-based teaching implementation group) and the control group each consist of 35 students., conditionsModule conditions: Midwifery Students, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intervention group (Case-based instruction group) Control group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Case-based instruction, outcomesModule primaryOutcomes measure: Determination of Critical Thinking Motivation, primaryOutcomes measure: Determination of Critical Thinking Motivation, secondaryOutcomes measure: Determining the level of Academic Motivation, secondaryOutcomes measure: Determining the level of Academic Motivation, secondaryOutcomes measure: Determining the status of access to information, secondaryOutcomes measure: Determining the status of access to information, secondaryOutcomes measure: Evaluation of satisfaction with the training methods used and the effect of training methods on perceptions of competence during clinical practice, secondaryOutcomes measure: Evaluation of satisfaction with the training methods used and the effect of training methods on perceptions of competence during clinical practice, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Kahramanmaras Sutcu Imam University, status: RECRUITING, city: Kahramanmaraş, state: Kahramanmaras, zip: 46050, country: Turkey, contacts name: Esra KARATAŞ OKYAY, PhD, role: CONTACT, phone: 05432125225, email: esrakaratas44@hotmail.com, contacts name: Pınar KARA, PhD, role: CONTACT, phone: 0507 957 0859, email: karapinar@hotmail.com, geoPoint lat: 37.5847, lon: 36.92641, hasResults: False